Navigation Links
First documented case of pest resistance to biotech cotton
Date:2/7/2008

not evolved resistance."

The field outcomes refute some experts' worst-case scenarios that predicted pests would become resistant to Bt crops in as few as three years, he said.

The only other case of field-evolved resistance to Bt toxins involves resistance to Bt sprays," Tabashnik said. He added that such sprays have been used for decades, but now represent a small proportion of the Bt used against crop pests.

The bollworm is a major cotton pest in the southeastern U.S. and Texas, but not in Arizona. The major caterpillar pest of cotton in Arizona is a different species known as pink bollworm, Pectinophora gossypiella, which has remained susceptible to the Bt toxin in biotech cotton.

Tabashnik and his colleagues' article, "Insect resistance to Bt crops: evidence versus theory," will be published in the February issue of Nature Biotechnology. His co-authors are Aaron J. Gassmann, a former UA postdoctoral fellow now an assistant professor at Iowa State University; David W. Crowder, a UA doctoral student; and Yves Carrire, a UA professor of entomology. Tabashnik and Carrire are members of UA's BIO5 Institute.

The U.S. Department of Agriculture funded the research.

"Our research shows that in Arizona, Bt cotton reduces use of broad-spectrum insecticides and increases yield," said Carrire. Such insecticides kill both pest insects and beneficial insects.

To delay resistance, non-Bt crops are planted near Bt crops to provide "refuges" for susceptible pests. Because resistant insects are rare, the only mates they are likely to encounter would be susceptible insects from the refuges. The hybrid offspring of such a mating generally would be susceptible to the toxin. In most pests, offspring are resistant to Bt toxins only if both parents are resistant.

In bollworm, however, hybrid offspring produced by matings between susceptible and resistant moths are resistant. Such a dominant
'/>"/>

Contact: Mari N. Jensen
mnjensen@email.arizona.edu
520-626-9635
University of Arizona
Source:Eurekalert  

Page: 1 2 3

Related biology technology :

1. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
2. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
3. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
4. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
5. Hologic Announces First Quarter Fiscal 2008 Operating Results
6. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
7. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
8. RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications
9. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
10. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
11. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First documented case of pest resistance to biotech cotton
(Date:6/2/2015)... 2, 2015   Hospira, Inc. (NYSE: ... that its partner, Celltrion – a global biopharmaceutical company – ... Surveillance Agency in Brazil – ... for use in Brazil . The ... and sells biosimilar infliximab in 26 European countries and ...
(Date:6/2/2015)... June 02, 2015 “Stem Cell Therapy to ... mainstream, and it is used often as an adjunct to ... practitioners are not yet aware or comfortable enough with the ... is most often reserved for the last resort cases - ... can barely lift a paw to get around. It is ...
(Date:6/2/2015)... June 2, 2015   Intrexon Corporation ... biology, announced today the appointment of Olivier ... Consumer Sector.  Mr. Jarry will lead the expansion ... and applications for consumer markets.  ... of experience in leading global life sciences and ...
(Date:6/2/2015)... 2, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapies primarily ... today announced that Dr. Pamela Pavco , ... the 23 rd World Congress of ... include in-depth presentations by world-class clinicians and/or ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4
... Shows No Thrombosis, Low MACE Rates ... Thirty Patients, ABBOTT PARK, Ill., March 13 ... first clinical trial of a,fully bioabsorbable drug eluting stent ... thrombosis, no clinically driven target,lesion revascularizations (retreatment of a ...
... call scheduled for 5:00 pm ET today, ... NPSP ) today reported 2007 financial results,and ... strategy to,develop the company,s late-stage product candidates in ... unmet,medical need., In line with its new ...
... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) today announced financial results ... well as 2008 financial guidance., Fourth Quarter and Year ... 2007 was $5.7 million compared with,$6.4 million for the fourth ... was $20.1 million compared with $36.5 million for the year,ended ...
Cached Biology Technology:The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4NPS Pharmaceuticals Reports 2007 Financial Results 2NPS Pharmaceuticals Reports 2007 Financial Results 3NPS Pharmaceuticals Reports 2007 Financial Results 4NPS Pharmaceuticals Reports 2007 Financial Results 5NPS Pharmaceuticals Reports 2007 Financial Results 6NPS Pharmaceuticals Reports 2007 Financial Results 7NPS Pharmaceuticals Reports 2007 Financial Results 8NPS Pharmaceuticals Reports 2007 Financial Results 9Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 2Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 3Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 4Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 5Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook 6
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... East Asia is where the wolf was tamed and became the ... But now researchers at the Royal Institute of Technology (KTH) in ... "For the first time in world history it is possible to ... in time, and how many wolves were tamed," says Peter Savolainen, ...
... and other aquatic fauna in recent centuries are not restricted ... that species in rivers and lakes worldwide also experienced sharp ... is frequently overlooked by natural resource managers, according to an ... , Authors Paul Humphries and Kirk Winemiller argue that as ...
... Three out of ten women who undergo polar body ... of polar body analysis (PBA) is described by researchers in ... edition of Deutsches rtzeblatt International , in which they ... Int 2009; 106(33): 533-8). Polar bodies are by-products of ...
Cached Biology News:Shifting baselines confound river restoration 2New developments in reproductive medicine 2
HSPBP1 Antibody...
golgi reassembly stacking protein 2, 55kDa...
...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: